Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

41.97 +0.12 (+0.29%)
Delayed Quote Updated: 3:05 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
News headline image
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' ↗
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. 
Via Benzinga
News headline image
3 No-Brainer Stocks to Buy With $200 Right Now ↗
A modest amount of money can go a long way on Wall Street when it's put to work in innovation-driven businesses. 
Via The Motley Fool
News headline image
Here's How Much $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
News headline image
Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today ↗
 
Via Benzinga
News headline image
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know ↗
 
Via Benzinga
News headline image
Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse ↗
The FTC is investigating Teva Pharmaceuticals for alleged misuse of inhaler patents to block generic competition and maintain high prices in the U.S. while selling the same products for less overseas. 
Via Benzinga
Topics Intellectual Property
News headline image
Dr. Reddy's Labs Stock Sees Improved Technical Strength ↗
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
Via Investor's Business Daily
News headline image
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Engages In Settlement Talks Over Medicare Kickback Allegations ↗
Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copaxone sales, risking up to $10 billion in damages. 
Via Benzinga
Topics Lawsuit
News headline image
Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know ↗
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly... 
Via Benzinga
Topics Lawsuit
News headline image
7 A-Rated Biotech Stocks Worth Betting on in June ↗
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
News headline image
What is a Bull Flag Pattern? Explanation and Examples
Learn how to identify and trade the bull flag pattern, which is a key tool for spotting continuations in bullish trends. 
Via MarketBeat
News headline image
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
2 Generic Drug Makers With Growing Runways
Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out. 
Via MarketBeat
Topics Intellectual Property
News headline image
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
News headline image
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch ↗
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
News headline image
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade ↗
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
News headline image
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
From Teva Pharmaceutical Industries Limited
Via Business Wire
News headline image
These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio? ↗
Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in your portfolio? 
Via Benzinga
News headline image
These 7 Stocks Surged Double-Digits and Have Double-Digits to Go
Stocks surging on earnings reports often continue moving higher over time. This is a look at seven that surged more than 10% on Q1 results. 
Via MarketBeat
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.